Abstract. Alzheimers disease (AD) is characterized by the deposition of b-amyloid peptides (Ab) and a progressive loss of neurons leading to dementia. Because hippocampal neurogenesis is linked to functions such as learning, memory and mood, there has been great interest in examining the effects of AD on hippocampal neurogenesis. This article reviews the pertinent studies and tries to unite them in one possible disease model. Early in the disease, oligomeric Ab may transiently promote the generation of immature neurons from neural stem cells (NSCs).
Introduction
Alzheimers disease (AD) afflicts~15 million people worldwide [1] . In the United States of America, more than 4 million people are suffering from AD, and their numbers are predicted to triple by 2050 [2] . The clinical symptoms of AD are exemplified by progressive deterioration of cognitive function, psychiatric problems and dementia [3] . Thus, persons afflicted with AD steadily lose their memory and ability to learn, reason, make judgments, communicate and carry out daily activities. Persistence of neurogenesis in the dentate gyrus of the hippocampal formation during adulthood was identified more than a decade ago [4] . Adult neurogenesis is a process by which new neurons are produced from neural stem/progenitor cells (NSCs) in the adult brain. Neural stem cells are the self-renewing, multipotent cells that are capable of unlimited proliferation and generating the central nervous system (CNS) phenotypes such as neurons, astrocytes and oligodendrocytes [5] . On the other hand, progenitor cells are either multipotent or bipotent, have limited proliferation potential and lack self-renewal ability. Because of the difficulty in distinguishing NSCs from neural progenitors in vivo, classifying them as neural stem/ progenitor cells (NSCs) has been the norm in most of the in vivo studies. Adult neurogenesis occurs throughout life in two neurogenic regions of the brain: (i) the subventricular zone (SVZ) lining the lateral ventricles of the brain and (ii) the subgranular zone (SGZ) of the dentate gyrus in the hippocampal formation [6, 7] . In the rodent brain, proliferation of NSCs in the SVZ produces a large pool of neuroblasts which migrate into the olfactory bulb through a pathway called the rostral migratory stream. Once they reach the olfactory bulb, they differentiate into olfactory interneurons. On the other hand, proliferation of NSCs in the SGZ results in production of new granule cells and glia, which migrate mainly into the dentate granule cell layer (GCL, Fig. 1 ) In the GCL, they mature, send dendrites into the molecular layer and axons into the stratum lucidum of the CA3 via the dentate hilus where they make synaptic contacts with CA3 pyramidal neurons. Many life conditions can modulate the rate of hippocampal neurogenesis. The positive regulators of neurogenesis in the young brain include physical exercise [8, 9] and environmental enrichment [10] . However, brain injury inflicted through acute seizures or cerebral ischemia also triggers increased neurogenesis in the young adult brain [11, 12] but not in the aged brain [13] . In addition, neurogenesis is sensitive to the concentrations of a variety of neurotrophic factors and molecules [14] . The negative regulators include stress [15] , aging [16 -19] and chronic neurodegenerative conditions such as temporal lobe epilepsy [20] . Hippocampal neurogenesis is considered important for functions such as learning, memory and mood, demonstrated by the increased survival of newborn neurons in the hippocampus through hippocampal-dependent learning and memory tasks [21 -23] and through increased neurogenesis observed after antidepressant therapy [24] . The goals of this review are to discuss the extent of changes in dentate neurogenesis during AD, the role of AD pathology in altering the behavior of NSCs and their differentiation in the hippocampus, and the potential strategies for improving neurogenesis in AD brain.
Basic pathology
The hallmark of AD is the accumulation of extracellular senile plaques and intracellular neurofibrillary tangles [25, 26] . Typically, these plaques are formed in the brain many years before the onset of clinical signs of AD. The primary proteinaceous component of the senile plaques is Ab . Ab is produced by cleavage of the amyloid precursor protein (APP) at the N-and C-terminal end by b-and g-secretase, respectively. Two Ab proteins are produced by g-secretase that are 40 or 42 amino acids long and termed Ab 40 and Ab 42 , respectively [28] . The carboxy-terminal length of the Ab molecule was shown to be critical for determining the formation rate of Ab fibrils: Ab 42 precipitates and forms fibrils much more easily than Ab 40 [29] . Typically, Ab 42 constitutes only 10% of the total secreted Ab , but in vitro experiments have shown that its fraction may be significantly increased in AD [31] . There is also evidence in mouse models that Ab 40 inhibits amyloid deposition [32] . Thus, Ab 42 has predominantly been used by investigators to examine the effects of Ab on neurogenesis. . Doublecortin immunostaining of the dentate gyrus from a normal adult rat brain showing newly born neurons (A) (magnified view of a region from A highlights the morphology of newly born neurons, B). Cell bodies of newly born neurons are located in the subgranular zone (SGZ) whereas their dendrites extend through the granular cell layer (GCL) into the molecular layer (ML) These doublecortin-positive cells migrate mainly into the GCL where they mature into full-fledged granule cells. Granule cells send axons into the stratum lucidum of the CA3 via the dentate hilus (DH) where they make synaptic contacts with the CA3 pyramidal neurons.
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Familial Alzheimer disease
Several genetic mutations have been suggested to contribute to early onset AD usually around 50 years of age. Three genes have been implicated in the development of familial AD (FAD): bAPP, presenilin-1 (PS-1) and presenilin-2 (PS-2). Mutation in bAPP can occur at position 717 (Indiana mutation) substituting valine for isoleucine, phenylalanine or glycine [33 -35] . Mutations can also occur at positions 670/671. This mutation was first discovered in a Swedish family with early AD and is referred to as the Swedish double-mutation [36] . Mutations in APP in FAD are close to the sites of cleavage of APP for band g-secretases which may promote the formation of Ab. The Swedish double-mutation, for example, enhances the activity of b-secretase [31, 37, 38] , and the 717 mutation increases fractional Ab 42 expression [39] . PS-1 and PS-2 are an integral part of the gsecretase complex [40, 41] , and mutations in these genes have also been shown to cause an increase in Ab 42 production [42 -44] .
Animal models of AD
As neurogenesis in AD has been studied in animal prototypes, it is important to understand the underlying pathology in these models. Transfection of human APP is necessary to cause Ab deposition in mouse models; however, increased concentrations of mouse APP do not have any effects [45] . To study neurogenesis, human APP (hAPP) has been used as a transgene with either the Swedish double-mutation or mutations at position 717. Expression of hAPP is usually driven in animal models by neuron-specific promoters such as PDGF, Thy-1 or Thy-1.2 or nonspecific promoters such as hamster PrP [46] . The PDAPP transgenic line bears the mutation at position 717 and is driven by the neuron-specific PDGF promoter [47] . At the age of 6 months, these animals start to develop deposits of Ab peptide in the hippocampus [48] . Transgenic mice over-expressing the Swedish double-mutation (APP swe ) develop late-onset amyloid pathology [49] . Transgenic animals with missense mutations of PS-1 show accelerated amyloid pathology in the brain by the preferential production of Ab 42 [44] while their cognitive impairment is modest [50] . Doubly transgenic mice (APPPS1 mice) with the Swedish doublemutation in APP and a point mutation in PS-1 at position 166 may show cerebral amyloidosis as early as 6 -8 weeks post-partum [51] . Deletion of exon 9 in PS-1 co-expressed with the Swedish double-mutation leads to Ab deposits at the age of 4 -5 months [52, 53] .
A triple-transgenic mouse model harboring PS1, APP and tau gene mutations has also been developed in order to more closely mimic the AD process [54] . Extraction of Ab 40 and Ab 42 from post-mortem brain has shown that total levels of these peptides do correlate with the severity of disease progression [57] . Plaque density and total volume of amyloid, however, correlate poorly with the severity of dementia in AD [58, 59] . This observation has led to the hypothesis that Ab 42 oligomers are primarily responsible for causing the cognitive decline in AD [60] . This theory is supported by the fact that Ab 42 oligomers have been found to be at least as toxic as Ab 42 fibrils [61] . Soluble oligomers have also been found to be potent inhibitors of long-term potentiation and might therefore cause the early memory loss seen in AD [62] . A 56-kDa soluble amyloid-b oligomer (Ab*56) was isolated from an Alzheimer mouse model that showed cognitive impairment before neurodegeneration or amyloid-b pathology. Infusion of this oligomer into young rats reproduced the cognitive impairment seen in the mouse model [63, 64] . Immunization of a transgenic APP mouse line with an antibody that recognizes soluble oligomers led to significant cognitive improvement [65] . Thus, there is significant evidence that Ab 42 oligomers play an important role in the clinical pathology of AD.
Effect of AD on neurogenesis in human studies
Post-mortem studies Post-mortem studies on the status of neurogenesis in human Alzheimer patients have been contradictory. One group of investigators reported an increase in hippocampal neurogenesis in AD after performing Western blot and immunohistochemical analyses on post-mortem tissue [66] . Using markers of immature neuronal cells such as Turned On After Division (TOAD)/Ulip/CRMP-4 (TUC-4), polysialated neural cell adhesion molecule (PSA-NCAM), doublecortin (DCX) and NeuroD, they reported an increased density of such cells in the granule cell layer of Alzheimer brains in comparison to control subjects ( Fig. 2) In addition, the overall expression of these marker proteins was found to be increased in Western blot analyses of the hippocampus. The AD brains also exhibited potential new neurons in the CA1 region of the hippocampus. Additionally, the authors reported increased levels of proliferating cell nuclear antigen (PCNA) in the hippocampus of AD brains, suggesting that an increased proliferation of cells likely occurs in the hippocampus of AD brains. However, the possibility of binding of PCNA antibodies to apoptotic cells in the AD brain needs to be ruled out to confirm this finding [67, 68] . Additionally, rigorous quantification of changes in the levels of the above-mentioned proteins will be helpful in future studies for further confirmation of their increase in AD. Based on their data, the authors suggest that AD triggers neurogenesis in an attempt to replace lost neurons, leading to an increased number of immature neurons in the GCL. However, it should be noted that neurogenesis in senile AD cases may also reflect the effects of AD drug therapy. This is because a recent study suggests that administration of AD drugs such as tacrine, galantamine or memantine to mice increases neurogenesis in neurogenic regions of the brain [69] .
Contrasting with this report are data that found no increased neurogenesis in the presenile Alzheimer hippocampus in post-mortem tissue [70] . Semi-quantitative scoring of DCX showed no difference between Alzheimer patients and normal subjects. Immunohistochemistry for Ki-67, an endogenous marker of cell proliferation that does not undergo post-mortem decay, revealed no change in cell proliferation in the neuron-rich dentate granule cell layer of AD brains.
Although there was an increased density of Ki-67+ cells in CA1 and CA3 regions of the hippocampus, all of these cells appeared to be glia and other nonneuronal cells. Thus, in contrast to the results obtained in senile AD cases, it appears that presenile AD brains do not exhibit increased neurogenesis. In another study, neural precursor cells were isolated from post-mortem Alzheimer patients and propagated in proliferative medium [71] . It was shown that isolated precursor cells could be differentiated into TuJ-1-positive neurons and GFAP-positive astrocytes. The viability of the neural precursor cells harvested from Alzheimer patients, however, was significantly lower than in an age-matched control group. Furthermore, these cells exhibited earlier senescence, characterized by discontinuation of proliferation after 2 weeks of initial plating compared to 5 weeks in the control group. Progenitor cell activity in the SVZ of AD brains has been examined using markers such as Nestin and Musashi1 [72] . A ninefold decrease in Musashi1 immunoreactivity in the SVZ of patients with AD was seen in comparison to control brains. On the other hand, the number of GFAP-and nestin-positive cells was significantly increased in immunohistochemical studies. Additionally, a potential decrease in progenitor cell numbers was associated with cortical cholinergic loss. Thus, AD may cause depletion of subependymal progenitor cells by pushing their cell fate to immature neurons or glial cells. It is plausible that decreased activity of NSCs in the SVZ of AD brains decreases the potential for spontaneous replacement of lost neurons in the cerebral cortex of AD brain.
Neurogenesis in Down syndrome
Neurogenesis has also been investigated in Down syndrome since these patients typically present with AD by 40 -50 years of age [73] . Neurospheres were isolated from post-abortion fetal tissue, grown for 10 weeks and then plated for differentiation. Considerably fewer neurons emerged after in vitro differentiation of neurospheres derived from the brain of Down syndrome patients compared to controls while the numbers of glial cells remained unchanged. It is unclear though whether the number of neurons generated from these neurospheres was decreased due to increased apoptosis or due to a preferential differentiation of neurosphere cells into glia.
Effect of AD on neurogenesis in cell culture models
In vitro effect of Ab 42 on proliferation and differentiation of human NSCs Several investigators have looked at the effects of Ab 42 on human neural progenitor cell proliferation in vitro.
Since Ab induces caspase-mediated apoptosis in mature neurons [74 -76] , the question arises whether it has similar effects on human neural progenitor cells. Indeed, aggregated Ab 42 was found to be toxic to human NPCs derived from cortical fetal tissue at a concentration of 1 mM in vitro, increasing the percentage of apoptotic cells threefold in one study [77] . What are the differences in these studies and how can the discrepant results between the human and rodent data be reconciled? One possibility is that different tissue sources might have contributed to the variant observations. On the other hand, different preparations of Ab 42 might have played a major role in obtaining different effects on neurogenesis and progenitor cell proliferation. For example, in the human study, Ab 42 was only aggregated overnight while it was aggregated for 3 days in one rodent study [77, 80] . Thus, the fraction of monomeric Ab 42 might have been higher in the human cell culture experiments. This could have led to decreased neurogenesis and impaired progenitor proliferation as similarly observed for monomeric Ab 42 at concentrations of 5 mM or higher in rodents [79] .
In conclusion, only oligomeric Ab 42 was found to be neurogenic, while monomeric and fibrillary Ab 42 were not shown to increase neurogenesis or progenitor cell proliferation in cell culture experiments (Table 1 summarizes all results). Since fibrillary Ab 42 is the prevalent aggregation state in the end-stage Alzheimer brain, one potential mechanism might involve decreased neurogenesis and NSC proliferation at the final stages of the disease, while the formation of Ab 42 oligomers at earlier stages may transiently promote the initial steps of neurogenesis.
In vitro effect of APP on human NSC differentiation Soluble APP (sAPP) has also been implicated in hampering neurogenesis in AD by shifting the cell fate of human NSCs to a glial as opposed to a neuronal lineage decision. Treatment of human NSCs with sAPP dose-dependently increased the population of GFAP-positive cells from an average of 45 % in controls (no sAPP) to an average of 83 % with the highest concentration of sAPP treatment [81] . Because apoptosis-related gene expression was not observed in human NSCs after sAPP treatment, neuronal apoptosis does not seem to be the cause of increased percentages of glia. In addition to its effect on neural lineage determination, sAPP also promoted the differentiation of human NSCs in vitro, an effect that was reversible by administering an antibody against the growth-factor-like domain of APP.
Role of fibroblast growth factor-2 and neurotrophic factors Since the levels of fibroblast growth factor 2 (FGF-2) are up-regulated in the hippocampus of AD patients [82, 83] while the levels of several neurotrophic factors are down-regulated [84, 85] , the hypothesis that a strong mitogen such as FGF-2 prevents neuronal differentiation and maturation in the absence of other neurotrophic factors was investigated in vitro [86] . Adult rat hippocampal progenitors were isolated and cultured for 7 days with different concentrations of FGF-2. The cultures treated with the highest concentration of FGF-2 showed the most prominent rise in immature and dividing cells whereas the number of mature neuronal cells strongly decreased in this setting. The FGF-2 treatment did not affect the glial lineage determination, only differentiation into neu- Review Article 2377 rons was found to be decreased. When treated with neurotrophic factors such as ciliary neurotrophic factor (CNTF), glial-derived neurotrophic factor (GDNF) and insulin-like growth factor-1 (IGF-1), the neuronal differentiation was rescued, demonstrated by a rise in the number of TuJ-1-positive cells. The neurogenic activity of CNTF was shown to be neutralized with an antibody to CNTF. This in vitro model demonstrated that elevated levels of FGF-2 in AD may prevent neuronal differentiation and maturation in the absence of other neurotrophic factors. This is in contrast to the increased neurogenesis observed in the naive aging hippocampus following exogenous FGF-2 administration [87] . Thus, it appears that factors that promote neuronal differentiation are critical for improving hippocampal neurogenesis in AD. Table 2 summarizes the experimental design of the discussed cell culture experiments.
Role of basic helix-loop-helix transcription factors
To elucidate the effects of Ab 42 on the gene expression profile of neural progenitor cells, neurospheres from E17 rat cerebral cortices were grown for 7 days, and their total RNA was hybridized to cDNA macroarrays after neurosphere dissociation and plating [88] . It was shown that Ab 42 up-regulates mammalian achaeteschute homolog-1 (Mash-1) while Olig2 was downregulated. The amount of increase in Mash-1 expression was found to be independent of the aggregation state of Ab 42 . Subsequently, the effects of Mash-1 over-expression and Olig2 down-regulation were assessed by using over-expression constructs and siRNA in vitro. Both Mash-1 over-expression and Olig2 silencing were found to promote neuronal differentiation by increasing the expression of the neuronal marker b-tubulin-III. However, in the setting of Ab 42 -induced Olig2 depletion, Mash-1 overexpression led to apoptosis. Thus, down-regulation of Olig2 and over-expression of Mash-1 in neural progenitor cells by Ab 42 may switch the cell fate from neuronal differentiation to cell death.
Possible role for seladin-1 in neural stem cell vulnerability in AD Seladin-1 is a gene that has been implicated in conferring resistance to AD-associated neurodegeneration and shown to be down-regulated in AD [89] .
Human mesenchymal stem cells (hMSCs) derived from bone marrow biopsies were found to have high levels of seladin-1 [90] . As soon as the hMSCs were differentiated into neuronal-like phenotypes, the intracellular concentration of seladin-1 decreased significantly. High concentrations of seladin-1 were also found in the normal adult hippocampus which led the authors to conclude that this gene is primarily expressed by neural progenitors. However, no proof for their hypothesis was given. Decreased expression of seladin-1 in neural progenitors in AD might make these cells more susceptible to oxidative stress and cell death.
Effect of AD in animal models
Increased birth of immature neurons in the GCL Another clue regarding the controversy between increased or decreased neurogenesis in AD comes from AD mouse models. Supporting the post-mortem data of increased neurogenesis, a greater density of immature neurons positive for DCX could be demonstrated in the outer granule cell layer of PDAPP mice compared to wild-type mice [91] . Interestingly, although there was an increased proliferation of progenitors, fewer of these neurons survived after 4 weeks with respect to the control. There was a trend toward increased apoptosis of cells in the outer granule cell layer, although the numbers were not significant. The percentage of progenitors that had undergone differentiation into mature neurons as shown by dual immunofluorescence for BrdU and NeuN was, however, unchanged between wild-type and the disease model, demonstrating that there was no change in the cell fate decision of neural progenitors in the setting of APP over-expression. Looking at the SGZ, an age-dependent decrease in neurogenesis was seen which outweighed the changes in the outer granule cell layer. Therefore, impaired neurogenesis was considered the overall predominant pathology in this mouse model of AD. The decrease in neurogenesis was, however, not associated with an age-dependent loss of dentate granule neurons. Furthermore, abnormal maturation of BrdU-positive cells into neurons was demonstrated based on their irregular shapes and perpendicular rather than parallel orientation to the GCL. Punctuate BrdU staining which is typical for cell differentiation and maturation was also observed to be decreased [92] .
The investigators who had shown increased neurogenesis in AD post-mortem specimens validated their findings in mice carrying both the Indiana and Swedish double-mutations [93] . They were again able to show an increase in immature neuronal cells by staining for DCX and NeuroD. Thus, AD may promote the generation of early, immature neurons in the dentate gyrus.
Impaired neurogenesis in PS-1 and APP mutant mice
The effect of PS-1 was tested in a mouse model in vivo by neuron-specific over-expression of wild-type PS-1 or the P117L mutant form found in familial AD [94] . Both PS-1 constructs significantly decreased the number of BrdU-positive cells in the dentate gyrus in the transgenic mice compared to wild-type mice. Over-expression of human wild-type, but not FAD mutant PS-1, however, was shown to promote the generation of Toad64-and b-III-tubulin-labeled early post-mitotic neurons. Thus, PS-1 was demonstrated in this transgenic model to enhance the survival and differentiation of neural progenitor cells. PS-1 FAD mutant mice were then subsequently shown to have impaired neurogenesis [95] . Fewer BrdUlabeled cells became new neurons in the hippocampus of P117L FAD mutant transgenic animals, as demonstrated by a decrease in the number of b-III-tubulinlabeled early post-mitotic neurons and calbindinlabeled mature granule cells. Mutant and wild-type mice showed, though, similar numbers of TUC-4-and PSA-NCAM-immunoreactive immature neurons. Thus, mutant PS-1 might block the maturation and survival of newly generated immature neurons in the adult rodent hippocampus. Consistent with these data, decreased neurogenesis was also observed in another study of mutant PS-1 mice with double-staining for BrdU and a mature neuronal marker (NeuN) [96] . A study in 12 to 14-month-old mice over-expressing a mutant form of APP (the Swedish mutation APP695) demonstrated decreased neurogenesis as well [77] .
Recently, there has been more evidence that AD impairs the maturation of neuronal progenitors into neurons [97] . Short-term survival of cells, assessed by BrdU labeling for 12 days, was not found to be altered in an APP/PS-1 mouse model in the dentate gyrus. However, after 30 days, a significantly lower fraction of BrdU-positive cells co-expressed the mature neuronal marker NeuN in APP single-transgenic and APP/PS1 double-transgenic mice. Thus, progenitor proliferation was not found to be impaired, but fewer progenitors managed to differentiate into mature neurons compared to control mice in this AD model. Other experiments with APP/PS-1 mice have shown evidence for an earlier disruption of hippocampal neurogenesis [98] . Decreased neurogenesis was reported in mice carrying targeted mutations in both APP and PS-1. These double knock-in mice developed aging-and region-dependent amyloid deposition starting around 6 months, and by 9 months displayed activated microglial cells coupled with amyloid. By 9 months of age, there was also a three-fold decrease in the number of putative NSCs positive for the marker mini chromosome maintenance protein 2 (MCM2) [99] , and a two-fold decrease in the number of DCXpositive immature neurons. Furthermore, the decline observed in dentate neurogenesis at 9 months persisted at 18 months of age. Impaired neurogenesis was also evident through quantitative Western blot analysis of DCX content in this study. However, the decrease was restricted to the hippocampus, as the olfactory bulb neurogenic system showed no changes. A summary of the work on neurogenesis in AD animal models and post-mortem specimens is given in Table 3 .
Possible model for the effect of AD on neurogenesis
Many experimental studies have been performed in recent years to elucidate the effect of AD on neurogenesis. Some of the studies at first seem to be in disagreement. However, considering that investigators studied different post-mortem patient populations, cell culture and animal models and used the term neurogenesis with respect to different stages of neuronal maturation, a common theme can be recognized in the majority of the works published. Most studies suggest that neural progenitor proliferation in the dentate gyrus is not impaired, and progenitor cells are able to differentiate into early neuronal stages. The pathology seems to come into play when these immature neurons try to accomplish the steps necessary to differentiate into mature neurons. AD might inhibit the maturation of these early non-functional neurons, leading to a decrease in the number of new Cell. Mol. Life Sci. Vol. 65, 2008 Review Article neurons that integrate into the functional hippocampal circuitry. Figure 3 summarizes some of the work done in the field showing possible mechanisms by which neuronal maturation is inhibited. Considering the above, the potential NSC-based therapies for AD need to focus on providing a suitable microenvironment for differentiation of the progeny of NSCs into functional neurons that incorporate appropriately into the brain circuitry. Stimulating the proliferation of endogenous NSCs without additional treatment for neuronal differentiation of newly born cells might not improve the patients condition. Additionally, as neurogenesis is limited to certain regions such as the dentate gyrus of the hippocampus and SVZ [100, 101] , there is no clear evidence so far for such neurogenesis in the adult hippocampus following similar neurodegeneration. Additionally, new neurons generated from NSCs in the adult dentate gyrus following various types of hippocampal injury have not shown a capability for either migrating into the CA1 or CA3 regions or differentiating into hippocampal CA1 or CA3 pyramidal neurons. Rather, the phenotypic differentiation of new neurons generated from NSCs of the dentate gyrus is restricted to the formation of mostly dentate granule cells and some interneurons [102, 103] . Thus, the extent of neurogenesis in the dentate gyrus is unlikely to have any influence on CA1 neuronal survival in AD, even though the CA1 subfield is the hot spot of neurodegeneration in AD. From this perspective, grafting of NSCs into specific regions of the brain appears critical for replenishing the lost neurons in AD. Nevertheless, transplantation of NSCs without additional treatment for priming the microenvironment may not improve the patients condition because grafted NSCs are unable to differentiate fully into mature neurons in the hostile microenvironment prevailing in the AD brain. One of the keys to AD pathology may lie in the impaired differentiation of neuronal progenitors which cannot be addressed by cell transplantation alone. Infusion of neurotrophic factors or drugs capable of promoting the final steps of neuronal differentiation seems to be a valid approach for increasing neurogenesis in the AD brain based on the data summarized in this review. Indeed, infusions of nerve growth factor in aged animal models have been shown to increase cognitive function [104, 105] . A phase 1 clinical trial of nerve growth factor gene therapy for AD has been performed which showed that it is safe to transplant fibroblasts genetically engineered to express NGF into the forebrain [106] . Moreover, mini-mental status examination of the transplanted patients suggested a slowing in the rate of cognitive decline. Other strategies that may be beneficial for enhancing neuronal differentiation and survival in AD include exposure to an enriched environment in the form of new learning and cognitive exercise, simple physical exercise such as running and administration of neuronal differentiation factors such as BDNF. In fact, studies in animal models have shown increased neurogenesis in the naive aged hippocampus and/or the hippocampus with AD pathology following exposure to an enriched environment [107 -110] and physical exercise [9] . Similarly, peripheral administration of BDNF has been found to increase neurogenesis in the injured aged hippocampus [111] . Once a suitable microenvironment permissive for neuronal differentiation has been created, cell replacement therapies may play a role in replenishing lost neurons in a second treatment step. Grafting of NSCs or neurons derived from NSCs in vitro appears imminent if the hypothesis turns out be correct that the pools of endogenous NSCs in the AD brain exhibit depletion in number through premature early differentiation. Thus, NSC grafting may be important not only for replacing the degenerated neurons but also for restoring the pool of cycling progenitors so that significant neurogenesis continues even at later stages of the disease. Furthermore, additional studies are required to address fully the complexity of AD with respect to neurogenesis. Current research has mostly focused on the response of neurogenesis to Ab. Other disease models need to be investigated that integrate the complexity of the disease, including neurofibrillary tangles, dystrophic neuritis, increased cytokine activation and impairments in mitochondrial function.
Since new animal models have been developed that more closely mimic AD pathology [54] , the future holds promise that we will gain further insight into the impact of AD on neurogenesis.
